Long-term follow-up after high-dose therapy for high-risk multiple myeloma

Bone Marrow Transplantation
B BarlogieR Alexanian

Abstract

Between 1985 and 1990, 133 patients with advanced multiple myeloma (MM) (74% resistance; 41% resistant relapse, RR) were treated with five high-dose therapy (HDT) regimens including: melphalan < or =100 mg/m2 (MEL 100) (46 patients); MEL 100 plus GM-CSF (24 patients); MEL 140 plus autologous bone marrow transplantation (ABMT) (eight patients); MEL 140 plus TBI 850 cGy plus ABMT (37 patients); and thiotepa 750 mg/m2 (THIO 750) + TBI 850 cGy plus ABMT (18 patients). The median follow-up of alive patients as of December 1997 was 9 years. Overall, 17% experienced treatment-related mortality within 60 days (TRM) and 12% achieved stringently defined complete remission (CR) with a median duration of 16 months; four of 16 patients (25%) remain in CR at 10 years. The median durations of event-free survival (EFS)/overall survival (OS) were 6/15 months. Superior EFS/OS were noted with MEL 100 plus GM-CSF and the two TBI-containing regimens (9/24 months among 79 patients) compared to the remaining 54 patients receiving MEL < or =100 or MEL 140 plus ABMT (3/5 months) (P = 0.0001/0.0001, respectively). Multivariate regression analyses (MVA) were performed so that, despite patient heterogeneity among the five treatment groups, potentially rel...Continue Reading

Associated Clinical Trials

Citations

Jan 1, 1990·Journal of Cancer Research and Clinical Oncology·B Barlogie, J Epstein
Jan 1, 1990·Blut·B Barlogie
Sep 25, 2003·Cancer Biotherapy & Radiopharmaceuticals·Diely PichardoSteven Rosen
Apr 3, 1999·Current Opinion in Oncology·R L Schlossman, K C Anderson
Mar 16, 2002·The Cancer Journal·Kenneth C AndersonSamuel Waxman
Jan 3, 2001·AJR. American Journal of Roentgenology·F E LecouvetB Maldague
Nov 13, 2001·British Journal of Haematology·M RoviraE Montserrat
Aug 14, 2012·Leukemia & Lymphoma·Benjamin M CherryOla Landgren
Oct 31, 2006·Leukemia & Lymphoma·Susann SzmaniaFrits van Rhee
Jan 21, 2003·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Theresa HahnPhilip L McCarthy
Aug 18, 2012·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Margarita BlanesJavier de la Rubia
Mar 27, 2012·Hematology/oncology and Stem Cell Therapy·M-A BekadjaF Attaf
Nov 5, 2005·Oncology Nursing Forum·Joseph D Tariman, Stella Marie Estrella
Jul 20, 2005·Best Practice & Research. Clinical Haematology·Jean-Luc HarousseauHervé Avet-Loiseau
Oct 21, 2000·Bone Marrow Transplantation·D E ReeceJ D Shepherd
Jun 9, 2006·In Vitro Cellular & Developmental Biology. Animal·Maurizio Chiriva-InternatiEverardo Cobos
Nov 18, 2004·Oncology Nursing Forum·Sharon K Coon, Elizabeth Ann Coleman
Jul 1, 2016·World Journal of Transplantation·Annamaria Brioli
Jan 22, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·S Vincent RajkumarKenneth C Anderson
May 2, 2001·The Oncologist·N C Munshi
Nov 26, 2002·Hematology·Kenneth C AndersonG David Roodman
Feb 24, 2004·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Andrew M EvensRonald B Gartenhaus

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.